A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG
• •Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• •Pregnant or nursing women
• •Treatment with radiation therapy, surgery, chemotherapy, immunotherapy, or investigational therapy within four weeks prior to study entry
• •Unwillingness or inability to comply with procedures required in this protocol
• •Known active infection with HIV, hepatitis B, hepatitis C
• •Symptomatic brain metastases
• •Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
• •Patients who are currently receiving any other investigational agent